Marstacimab Therapy for Hemophilia Shows Long-term Efficacy and Safety
A recent study demonstrated significant efficacy and safety of monoclonal antibody Marstacimab in the long-term management of severe hemophilia A (HA) or hemophilia B (HB) without inhibitors. This outcomes from the pivotal Phase 3 BASIS study could revolutionize the approach to treat bleeding disorders. The findings were published in American Society of Hematology. Marstacimab enhances […]